Acinar Cell Adenocarcinoma of the Pancreas
19
0
0
16
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
10.5%
2 terminated out of 19 trials
88.9%
+2.4% vs benchmark
0%
0 trials in Phase 3/4
31%
5 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (19)
Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer
Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer
CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer
Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer
Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer
Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer
Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery
Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery
CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery
Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung
Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine